# Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

> **NCT05259696** · PHASE1,PHASE2 · COMPLETED · sponsor: **Palleon Pharmaceuticals, Inc.** · enrollment: 69 (actual)

## Conditions studied

- Oncology
- Melanoma
- Ovarian Cancer
- NSCLC
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Cancer
- CRC
- Colon Cancer
- Breast Cancer
- Gastric Cancer
- EGJ
- Esophagogastric Junction Cancer
- Head and Neck Cancer
- Urothelial Cancer
- Bladder Cancer

## Interventions

- **BIOLOGICAL:** E-602
- **BIOLOGICAL:** Cemiplimab

## Key facts

- **NCT ID:** NCT05259696
- **Lead sponsor:** Palleon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-11
- **Primary completion:** 2024-10-24
- **Final completion:** 2024-10-24
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259696, "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05259696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*